Full Text View
Tabular View
No Study Results Posted
Related Studies
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
This study is ongoing, but not recruiting participants.
Study NCT00012376   Information provided by National Cancer Institute (NCI)
First Received: March 3, 2001   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
sargramostim
bryostatin 1
More general drug interventions related to this trial
Adjuvants, Immunologic
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services